Singapore markets close in 7 hours 53 minutes

Quest Diagnostics Incorporated (DGX)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
148.48+2.72 (+1.87%)
At close: 04:03PM EST
148.60 +0.12 (+0.08%)
After hours: 07:21PM EST
Full screen
Trade prices are not sourced from all markets
Previous close145.76
Bid147.47 x 800
Ask148.65 x 800
Day's range145.73 - 148.62
52-week range120.40 - 158.34
Avg. volume1,078,432
Market cap16.91B
Beta (5Y monthly)0.97
PE ratio (TTM)14.57
Earnings dateN/A
Forward dividend & yield2.64 (1.81%)
Ex-dividend date17 Jan 2023
1y target estN/A
  • Business Wire

    DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection Test

    LA JOLLA, Calif. & PHOENIX, November 15, 2022--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today an agreement with Sonora Quest Laboratories (Sonora Quest), Arizona’s leading diagnostic laboratory, to expand access to enhanced melanoma detection. As a result of the agreement, Sonora Quest will be the exclusive laboratory in Arizona to offer the DermTech Melanoma Test to its vast network

  • Business Wire

    Achievers and Quest Diagnostics Win Gold in the 2022 Brandon Hall Group Excellence Technology Awards

    TORONTO, September 14, 2022--Achievers, an industry-leading employee experience software platform, announces its joint win of a Gold award by Brandon Hall Group with its customer case study of Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.

  • Business Wire

    Rite Aid and Quest Diagnostics Expand Access to COVID-19 PCR Testing Nationwide

    PHILADELPHIA & SECAUCUS, N.J., July 19, 2022--Rite Aid (NYSE: RAD) today announced it is collaborating with Quest Diagnostics (NYSE: DGX) to provide access to quality, COVID-19 molecular testing (polymerase chain reaction or similar nucleic acid amplification test) to help Rite Aid customers detect and prevent the spread of COVID-19.